Open Access. Powered by Scholars. Published by Universities.®
- Institution
- Publication
- Publication Type
Articles 1 - 9 of 9
Full-Text Articles in Medicine and Health Sciences
Natural Products Inhibitors Of Monoamine Oxidases—Potential New Drug Leads For Neuroprotection, Neurological Disorders, And Neuroblastoma, Narayan D. Chaurasiya, Francisco León Ph.D., Ilias Muhammad, Babu L. Tekwani
Natural Products Inhibitors Of Monoamine Oxidases—Potential New Drug Leads For Neuroprotection, Neurological Disorders, And Neuroblastoma, Narayan D. Chaurasiya, Francisco León Ph.D., Ilias Muhammad, Babu L. Tekwani
Faculty Publications
Monoamine oxidase inhibitors (MAOIs) are an important class of drugs prescribed for treatment of depression and other neurological disorders. Evidence has suggested that patients with atypical depression preferentially respond to natural product MAOIs. This review presents a comprehensive survey of the natural products, predominantly from plant sources, as potential new MAOI drug leads. The psychoactive properties of several traditionally used plants and herbal formulations were attributed to their MAOI constituents. MAO inhibitory constituents may also be responsible for neuroprotective effects of natural products. Different classes of MAOIs were identified from the natural product sources with non-selective as well as selective …
Serotonin Syndrome And/Or Opioid Withdrawal After The First Dose Of Naltrexone Hcl/Bupropion Hcl: An Observational Study, Stefanie J. Logothetis
Serotonin Syndrome And/Or Opioid Withdrawal After The First Dose Of Naltrexone Hcl/Bupropion Hcl: An Observational Study, Stefanie J. Logothetis
Pharmaceutical Sciences ETDs
In 2014, the Food and Drug Administration approved naltrexone HCl/bupropion HCl, a combination of an antidepressant and an opioid antagonist for chronic weight management therapy. Concurrent use of antidepressants and opioids has the potential to cause drug interactions involving serotonin syndrome. Our primary objective is to identify cases of serotonin syndrome and/or opioid withdrawal after initiation of naltrexone HCl/bupropion HCl. Our secondary objective is to assess which specific opioids are more likely to cause a drug interaction with naltrexone HCl/bupropion HCl. We performed an observational study by reviewing cases in the RADARS® database from January 2014 through December 2018. …
Experimental Pharmacological Research Regarding Some New Quinazolin-4-Ones Derivatives, Cornel Chiriță, Emil Ștefănescu, Cristina E. Zbârcea, Simona Negreș, Mihaela Bratu, Diana C. Nuță, Carmen Limban, Ileana C. Chiriță, Cristina D. Marineci
Experimental Pharmacological Research Regarding Some New Quinazolin-4-Ones Derivatives, Cornel Chiriță, Emil Ștefănescu, Cristina E. Zbârcea, Simona Negreș, Mihaela Bratu, Diana C. Nuță, Carmen Limban, Ileana C. Chiriță, Cristina D. Marineci
Journal of Mind and Medical Sciences
A series of new compounds with quinazolin-4-one structure, synthesized by the Pharmaceutical Chemistry Department of the Faculty of Pharmacy of the University of Medicine and Pharmacy “Carol Davila” Bucharest, was studied. Five of them were selected, conventionally named S1, S2, S3, S4, S5, and investigated in terms of their potential influence on the central nervous system (CNS). For this purpose, the antidepressant effect was determined using the forced swimming test; the anxiolytic/ anxiogenic effect was determined using the suspended plus-shaped maze (Ugo Basile); the effect on the motor activity was determined using the Ugo Basile activity cage; and the potential …
Worsening Choreoathetosis In Huntington's Disease With Fluoxetine, Lisdexamfetamine, And Melatonin: A Case Report., Clayton J Hamilton, Tysen K Timmer, Robert C Munjal, Fernando Cardozo-Pelaez, Ian R Mcgrane
Worsening Choreoathetosis In Huntington's Disease With Fluoxetine, Lisdexamfetamine, And Melatonin: A Case Report., Clayton J Hamilton, Tysen K Timmer, Robert C Munjal, Fernando Cardozo-Pelaez, Ian R Mcgrane
Articles, Abstracts, and Reports
Cognitive, affective, and sleep disturbances can be found in patients with Huntington's disease (HD), and medications used to treat these HD-related sequela can also impact HD-related movement disorders. We present the case of a 52-year-old Caucasian man with previously undiagnosed HD who exhibited significant choreoathetoid movements that improved with discontinuation of fluoxetine and lisdexamfetamine upon hospital admission. Following diagnosis of HD through genetic testing, he was administered 5mg of oral melatonin on two consecutive evenings, which resulted in worsening choreoathetosis. We calculated Naranjo adverse event scores of 5, 5, and 2 for fluoxetine, lisdexamfetamine, and melatonin, respectively, based on our …
The Design, Synthesis, And Biological Evaluation Of Aplysinopsin Analogs As Potential Neuromodulators, Kevin Lewellyn
The Design, Synthesis, And Biological Evaluation Of Aplysinopsin Analogs As Potential Neuromodulators, Kevin Lewellyn
Electronic Theses and Dissertations
Aplysinopsins are tryptophan-derived natural products that have been isolated from a variety of marine organisms and have been shown to possess a range of biological activities. Initial synthesis of a library of 50 aplysinopsin analogs revealed that of the 12 serotonin receptor subtypes and 34 other CNS receptors, aplysinopsin analogs shoa high affinity for the 5-HT2B and 5-HT2C receptor subtypes, with selectivity for 5-HT2B over 5-HT2C. Bromination at C-4 and C-5 of the indole ring resulted in greater binding affinities, with Ki's as low as 35 nM. In addition, biological evaluation of the MAO-A and MAO-B inhibitory activities of these …
Selecting Antidepressant Drugs For Management Of Depression In Primary Care (Part 1), Amresh Srivastava
Selecting Antidepressant Drugs For Management Of Depression In Primary Care (Part 1), Amresh Srivastava
Amresh Srivastava
No abstract provided.
Selecting Antidepressant Drugs For Management Of Depression In Primary Care (Part 2), Amresh Srivastava
Selecting Antidepressant Drugs For Management Of Depression In Primary Care (Part 2), Amresh Srivastava
Amresh Srivastava
No abstract provided.
Selecting Antidepressant Drugs For Management Of Depression In Primary Care (Part 1), Amresh Srivastava
Selecting Antidepressant Drugs For Management Of Depression In Primary Care (Part 1), Amresh Srivastava
Psychiatry Presentations
No abstract provided.
Selecting Antidepressant Drugs For Management Of Depression In Primary Care (Part 2), Amresh Srivastava
Selecting Antidepressant Drugs For Management Of Depression In Primary Care (Part 2), Amresh Srivastava
Psychiatry Presentations
No abstract provided.